Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
It shows 30-50% decreases in new and recurrent CUD in patients with diabetes or obesity who were treated with semaglutide vs non-GLP-1 medications
Professor Vlado Perkovic, professorial fellow at The George Institute, Provost at UNSW Sydney and senior author on the study, said: This research shows that GLP-1 receptor agonists could play an important role in addressing the global burden of non-communicable diseases
Ivezaj V, Saules KK, Schuh LM
Results Study population We identified 73,895 new users of GLP-1 receptor agonists and 113,207 new users of SGLT2 inhibitors (Table 1)
Damiana 2 references Newall CA, Anderson LA, Philpson JD
New strategies to improve clinical outcomes for diabetic kidney disease
US$ 21.56
US$ 22.86
US$ 28.07
US$ 24.98
US$ 21.72
US$ 23.19
